- Home
- MTR vs APVO Comparison
MTR vs APVO Comparison
Compare MTR & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | APVO |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MTR | APVO |
|---|---|---|
| Price | $5.12 | $6.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.3K | 23.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.03 | $0.25 |
| 52 Week High | $10.42 | $13.11 |
Technical Indicators
Market Signals| Indicator | MTR | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 44.23 |
| Support Level | $4.21 | $6.12 |
| Resistance Level | $5.90 | $7.65 |
| Average True Range (ATR) | 0.38 | 0.49 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 48.80 | 7.15 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.